Healthcare >> Sector Roundtables >> August 14, 2000

Roundtable Forum: Global Healthcare Investments In Biotechnology & Pharmaceuticals

YI RI, MD, PhD, is a Team Member at Mehta Partners LLC. He earned a combined advanced degree in Neuroscience from the Albert Einstein College of Medicine, New York, and has since worked as a science advisor evaluating patent portfolio, clinical trial studies and patent infringement issues. Profile
VIREN MEHTA, Pharm.D, is a Managing Member of Mehta Partners LLC. He has over 25 years of experience in the pharmaceutical and biotechnology industry, investment research, strategic advisory services, and asset management. Prior to founding Mehta and Isaly, where he pioneered an in- depth valuation methodology for biotechnology companies, Dr. Mehta was a part of the strategic planning team of the international division at Merck & Co. He earned a Doctor of Pharmacy from the University of Southern California, and an MBA from the Anderson School of Business at the University of California, Los Angeles. Profile
THOMAS DESCHAMPS is a Team Member at Mehta Partners LLC. He holds a Bachelor of Science degree in Cell Biology and worked in biomedical sales, providing consulting to the scientific research community. Mr. DesChamps is completing an MBA from the Stern School of Business at New York University. Profile
SUSHANT KUMAR, PhD, is a Team Member at Mehta Partners LLC. He has an extensive background in cancer research and has published numerous scientific articles. He was an American Cancer Society postdoctoral fellow at Harvard Medical School, where he conducted research in viral oncology. Dr. Kumar holds a Doctorate in Molecular Biology from UMDNJ ' Center for Advanced Biotechnology and Medicine. Prior to joining the firm, he was a senior technology analyst and consultant at Genesis Group Associates, where he covered a wide range of technology assessment and market research activities. Profile
NAVDEEP S. JAIKARIA joined Rodman & Renshaw, Inc., as a Senior Biotechnology Analyst in July 2003. Previously, Dr. Jaikaria was a Senior Biotechnology Analyst covering small and mid-cap biotechnology companies at Leerink Swann & Company as well as Mehta Partners. Dr. Jaikaria obtained his PhD at New York Medical College in Cell Biology and Anatomy and conducted postdoctoral research at The Rockefeller University. His scientific research focused on infectious diseases and cancer. Before joining Wall Street, Dr. Jaikaria also served as a consultant to biotechnology and pharmaceutical companies. Profile
MARK W. RAVERA, PhD, is a Team Member at Mehta Partners LLC. He has industry science experience (Aventis/RPR, Novartis/Sandoz, Schering Plough Research Institute) and global marketing exposure from Bristol- Myers Squibb and prior, was a Senior Scientist at DGI Biotechnologies, specializing in phage display technologies. His PhD (George Washington University) is in Genetics and his MBA was earned at Rutgers University. Profile
AJAY BANSAL is a Team Member at Mehta Partners. A seasoned industry manager, he most recently worked with Arthur D. Little's pharmaceutical consulting group and, prior to that, at Novartis, US and Switzerland. Mr. Bansal served as Executive Director, Strategy and Special Projects, in Ciba-Geigy's pharma division and holds Master's of Science degrees in Management from Kellogg Graduate School of Management and in Engineering and Operations Research from Northwestern University. He was a significant participant in the Ciba-Chiron partnership and has extensive consulting experience with Arthur D. Little and McKinsey & Company. Mr. Bansal is proficient in German. Profile
TWST: What distinguishes the approach that Mehta Partners takes to

investing in health care?

Mr. Mehta: Mehta Partners is dedicated to identifying the best

investment ideas anywhere in the